Drug intelligence / Profile preview

Mucograft (Geistlich Pharma AG)

Development stage
Unknown
Lead developer
Geistlich Pharma
Administration
Topical
01

Overview

Mucograft is a porcine-derived, non-cross-linked, resorbable collagen matrix designed specifically for soft tissue regeneration in the oral cavity. It features a unique three-dimensional bilayer structure: a compact macro-structure that provides mechanical stability while allowing open healing, and a thick, porous spongious part that supports blood clot stabilization and the ingrowth of soft tissue cells. Developed and manufactured by Geistlich Pharma, Mucograft serves as a xenogeneic alternative to autogenous connective tissue grafts (SCTG) in periodontal plastic surgery. It is primarily indicated for treating isolated gingival recession defects and for increasing the zone of keratinized tissue around teeth and implants. By acting as a scaffold for vascularization and tissue integration, it eliminates the need for a second surgical site for graft harvesting, thereby reducing patient morbidity and surgical time.

Brand names
MucograftMucoderm
Other names
porcine collagen matrixxenogeneic collagen matrixcollagen matrix

Beyond the preview

Go deeper on Mucograft (Geistlich Pharma AG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mucograft (Geistlich Pharma AG).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call